FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891732223> ?p ?o ?g. }

• W2891732223 endingPage "4524" @default.
• W2891732223 startingPage "4524" @default.
• W2891732223 abstract "4524 Background: Based on initial results from the phase 2 KEYNOTE-052 study (NCT02335424), pembro was approved for the treatment of cisplatin-ineligible patients with advanced UC. The results of the long-term follow-up analysis of KEYNOTE-052 are presented. Methods: Eligible patients were cisplatin ineligible (ECOG PS 2, CrCl ≥30 to <60 mL/min, grade ≥2 neuropathy/hearing loss, NYHA Class 3 heart failure), had advanced UC, and had received no prior chemotherapy for metastatic disease. Patients received pembro 200 mg IV Q3W for up to 24 months. Imaging was performed at wk 9, then Q6W for 12 months, and Q12W thereafter. The primary end point was confirmed ORR (RECIST v1.1, independent central review). Results: Efficacy and safety were assessed in 370 patients. Median age was 74 years; 10.8% of patients were ≥85 years old; 42.2% were ECOG PS 2; and 85.1% had visceral disease. As of the Nov 30, 2017, data cutoff, median (range) follow-up was 11.5 (0.1-31.3) mo. Confirmed ORR was 28.9% (95% CI, 24.3-33.8); 30 (8.1%) and 77 (20.8%) patients had complete response and partial response, respectively. Median duration of response was not reached (NR) (95% CI, 21.4 mo to NR); 82% and 68% of patients had a response of ≥6 and ≥12 mo, respectively. Median OS was 11.5 (95% CI, 10.0-13.3) mo; 6-and 12-mo OS rates were 67.2% and 47.5%, respectively. In patients with a PD-L1 expression combined positive score of ≥10 (n=110), ORR was 47.3% (95% CI, 37.7-57.0) and median OS was 18.5 mo (95% CI, 12.2 mo to NR). Median OS was NR (12.4 mo to NR) in patients with lymph node–only disease (n=51) and was 13.1 (95% CI, 11.0-16.8) mo in patients with ECOG PS 0/1 (n=214) and 9.7 (95% CI, 5.7-11.6) mo in patients with ECOG PS 2 (n=156). Treatment-related adverse events (AEs) occurred in 67.6% of patients; most common (≥15%) were fatigue (18.1%) and pruritus (17.8%). Grade ≥3 treatment-related AEs occurred in 20.3% of patients. Immune-mediated AEs occurred in 24.6% of patients. Conclusions: Pembro continues to be well tolerated and elicits clinically meaningful, durable antitumor activity in a broad spectrum of cisplatin-ineligible patients with advanced UC. Clinical trial information: NCT02335424." @default.
• W2891732223 created "2018-09-27" @default.
• W2891732223 creator A5001308517 @default.
• W2891732223 creator A5004167433 @default.
• W2891732223 creator A5010923222 @default.
• W2891732223 creator A5012800133 @default.
• W2891732223 creator A5018398274 @default.
• W2891732223 creator A5021767773 @default.
• W2891732223 creator A5024147987 @default.
• W2891732223 creator A5026717218 @default.
• W2891732223 creator A5032422193 @default.
• W2891732223 creator A5041610986 @default.
• W2891732223 creator A5064884168 @default.
• W2891732223 creator A5066133616 @default.
• W2891732223 creator A5071418777 @default.
• W2891732223 creator A5074756323 @default.
• W2891732223 creator A5082741754 @default.
• W2891732223 date "2018-05-20" @default.
• W2891732223 modified "2023-10-18" @default.
• W2891732223 title "Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)." @default.
• W2891732223 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.4524" @default.
• W2891732223 hasPublicationYear "2018" @default.
• W2891732223 type Work @default.
• W2891732223 sameAs 2891732223 @default.
• W2891732223 citedByCount "34" @default.
• W2891732223 countsByYear W28917322232018 @default.
• W2891732223 countsByYear W28917322232019 @default.
• W2891732223 countsByYear W28917322232020 @default.
• W2891732223 countsByYear W28917322232021 @default.
• W2891732223 countsByYear W28917322232022 @default.
• W2891732223 crossrefType "journal-article" @default.
• W2891732223 hasAuthorship W2891732223A5001308517 @default.
• W2891732223 hasAuthorship W2891732223A5004167433 @default.
• W2891732223 hasAuthorship W2891732223A5010923222 @default.
• W2891732223 hasAuthorship W2891732223A5012800133 @default.
• W2891732223 hasAuthorship W2891732223A5018398274 @default.
• W2891732223 hasAuthorship W2891732223A5021767773 @default.
• W2891732223 hasAuthorship W2891732223A5024147987 @default.
• W2891732223 hasAuthorship W2891732223A5026717218 @default.
• W2891732223 hasAuthorship W2891732223A5032422193 @default.
• W2891732223 hasAuthorship W2891732223A5041610986 @default.
• W2891732223 hasAuthorship W2891732223A5064884168 @default.
• W2891732223 hasAuthorship W2891732223A5066133616 @default.
• W2891732223 hasAuthorship W2891732223A5071418777 @default.
• W2891732223 hasAuthorship W2891732223A5074756323 @default.
• W2891732223 hasAuthorship W2891732223A5082741754 @default.
• W2891732223 hasConcept C121608353 @default.
• W2891732223 hasConcept C126322002 @default.
• W2891732223 hasConcept C126894567 @default.
• W2891732223 hasConcept C141071460 @default.
• W2891732223 hasConcept C203092338 @default.
• W2891732223 hasConcept C2776694085 @default.
• W2891732223 hasConcept C2777701055 @default.
• W2891732223 hasConcept C2777793932 @default.
• W2891732223 hasConcept C2778239845 @default.
• W2891732223 hasConcept C2780057760 @default.
• W2891732223 hasConcept C2780352672 @default.
• W2891732223 hasConcept C2780580376 @default.
• W2891732223 hasConcept C3020745361 @default.
• W2891732223 hasConcept C31760486 @default.
• W2891732223 hasConcept C535046627 @default.
• W2891732223 hasConcept C71924100 @default.
• W2891732223 hasConceptScore W2891732223C121608353 @default.
• W2891732223 hasConceptScore W2891732223C126322002 @default.
• W2891732223 hasConceptScore W2891732223C126894567 @default.
• W2891732223 hasConceptScore W2891732223C141071460 @default.
• W2891732223 hasConceptScore W2891732223C203092338 @default.
• W2891732223 hasConceptScore W2891732223C2776694085 @default.
• W2891732223 hasConceptScore W2891732223C2777701055 @default.
• W2891732223 hasConceptScore W2891732223C2777793932 @default.
• W2891732223 hasConceptScore W2891732223C2778239845 @default.
• W2891732223 hasConceptScore W2891732223C2780057760 @default.
• W2891732223 hasConceptScore W2891732223C2780352672 @default.
• W2891732223 hasConceptScore W2891732223C2780580376 @default.
• W2891732223 hasConceptScore W2891732223C3020745361 @default.
• W2891732223 hasConceptScore W2891732223C31760486 @default.
• W2891732223 hasConceptScore W2891732223C535046627 @default.
• W2891732223 hasConceptScore W2891732223C71924100 @default.
• W2891732223 hasIssue "15_suppl" @default.
• W2891732223 hasLocation W28917322231 @default.
• W2891732223 hasOpenAccess W2891732223 @default.
• W2891732223 hasPrimaryLocation W28917322231 @default.
• W2891732223 hasRelatedWork W2412619742 @default.
• W2891732223 hasRelatedWork W2461578584 @default.
• W2891732223 hasRelatedWork W2890639244 @default.
• W2891732223 hasRelatedWork W3004946703 @default.
• W2891732223 hasRelatedWork W3047040967 @default.
• W2891732223 hasRelatedWork W3112385753 @default.
• W2891732223 hasRelatedWork W4225141849 @default.
• W2891732223 hasRelatedWork W4247922271 @default.
• W2891732223 hasRelatedWork W57680343 @default.
• W2891732223 hasRelatedWork W2486250989 @default.
• W2891732223 hasVolume "36" @default.
• W2891732223 isParatext "false" @default.
• W2891732223 isRetracted "false" @default.
• W2891732223 magId "2891732223" @default.
• W2891732223 workType "article" @default.